Glucosamine sulfate in osteoarthritis therapy Glucosamin Glucosamine sulfate in osteoarthritis therapy Glucosamine sulfate in osteoarthritis therapy Glucosamin sulfate in osteoartrosis therapy
Abstract
Osteoarthritis (OA) is a chronic musculoskeletal disorder that affects a large part of the population. Symptomatic OA therapy is a combination of non-pharmacological and pharmacological procedures, the surgical treatment itself is the chapter.
Non-steroidal anti-inflammatory drugs, together with symptomatic slow-acting drugs in OA, called SYSADOA, are recommended in pharmacotherapy. SYSADOA positively affects the pain and stiffness, the most common symptoms of OA.
Characteristic for this drug group is a delayed effect, but it has the so-called carry over effect, which persists after six months of drug use. The efficacy of SYSADOA in the treatment of OA is a discussed unit; their administration to patients with OA is not consistently recommended by all specialist companies.
Glucosamine sulfate (GS) is one of SYSADOA with the largest number of clinical and experimental data on efficacy in OA treatment. The efficacy of GS as an OA-modifying disease has also been investigated; the results of a GS prevention study in patients with a high risk of OA knee development are interesting.
The great advantage of SYSADOA in general is their good safety profile with minimal serious side effects